Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders

  • 776 clinical trials
  • 267 recruiting
  • 243 conditions
  • 26 countries

Conditions in this area

243 conditions with trials, the busiest first

Obesity131Type 2 diabetes mellitus95Overweight64Type 1 diabetes mellitus42Endocrine ophthalmopathy27Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Diabetic retinal oedema15Type IIa hyperlipidaemia15Chronic kidney disease14Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic neuropathy13Alpha-1 antitrypsin deficiency11Fabry's disease10Hypoparathyroidism10Osteoporosis10Hypertriglyceridaemia9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Glucose tolerance impaired8+219

Clinical trials in Metabolism and nutrition disorders

776 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

776 clinical trials

Type 2 diabetes mellitus+1

Recruiting

Study of once weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes and chronic kidney disease on basal insulin

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus+2

Recruiting

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Recruiting

Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Diabetes mellitus+2

Recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ASC30 sodium
  • Sponsor:Ascletis Pharma (China) Co. Ltd.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Recruiting

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Recruiting

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Recruiting

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide81 clinical trialsSodium Chloride26 clinical trialsDapagliflozin24 clinical trialsTirzepatide20 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsColecalciferol14 clinical trialsPlacebo14 clinical trialsZenagamtide14 clinical trials
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.